JP2014532751A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532751A5
JP2014532751A5 JP2014540552A JP2014540552A JP2014532751A5 JP 2014532751 A5 JP2014532751 A5 JP 2014532751A5 JP 2014540552 A JP2014540552 A JP 2014540552A JP 2014540552 A JP2014540552 A JP 2014540552A JP 2014532751 A5 JP2014532751 A5 JP 2014532751A5
Authority
JP
Japan
Prior art keywords
compound according
cancer
der
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014540552A
Other languages
English (en)
Japanese (ja)
Other versions
JP6073910B2 (ja
JP2014532751A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2012/052786 external-priority patent/WO2013068755A1/en
Publication of JP2014532751A publication Critical patent/JP2014532751A/ja
Publication of JP2014532751A5 publication Critical patent/JP2014532751A5/ja
Application granted granted Critical
Publication of JP6073910B2 publication Critical patent/JP6073910B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014540552A 2011-11-09 2012-11-09 5−(ピリジン−2−イル−アミノ)−ピラジン−2−カルボニトリル化合物及びその治療使用 Active JP6073910B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557457P 2011-11-09 2011-11-09
US61/557,457 2011-11-09
PCT/GB2012/052786 WO2013068755A1 (en) 2011-11-09 2012-11-09 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use

Publications (3)

Publication Number Publication Date
JP2014532751A JP2014532751A (ja) 2014-12-08
JP2014532751A5 true JP2014532751A5 (https=) 2015-12-10
JP6073910B2 JP6073910B2 (ja) 2017-02-01

Family

ID=47178213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014540552A Active JP6073910B2 (ja) 2011-11-09 2012-11-09 5−(ピリジン−2−イル−アミノ)−ピラジン−2−カルボニトリル化合物及びその治療使用

Country Status (10)

Country Link
US (3) US9040540B2 (https=)
EP (1) EP2776417B1 (https=)
JP (1) JP6073910B2 (https=)
CN (1) CN104105696B (https=)
AU (1) AU2012335409B2 (https=)
BR (1) BR112014010938A2 (https=)
CA (1) CA2849566C (https=)
ES (1) ES2709003T3 (https=)
RU (1) RU2641693C2 (https=)
WO (1) WO2013068755A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6073910B2 (ja) 2011-11-09 2017-02-01 キャンサー・リサーチ・テクノロジー・リミテッド 5−(ピリジン−2−イル−アミノ)−ピラジン−2−カルボニトリル化合物及びその治療使用
ES2624307T3 (es) 2012-05-15 2017-07-13 Cancer Research Technology Ltd 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo y usos terapéuticos del mismo
CZ306322B6 (cs) 2014-12-17 2016-11-30 Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové Substituovaný 2-(2-fenylhydrazinyl)pyrazin, způsob jeho přípravy, jeho použití a farmaceutický přípravek ho obsahující
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
CN110872277B (zh) * 2019-11-14 2021-06-04 浙江大学 N-取代芳环-2-氨基嘧啶类化合物及用途
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Chk1抑制劑之合成方法
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773778A (en) 1972-01-24 1973-11-20 Squibb & Sons Inc Sulfur derivatives of pyrazolo (3,4-b)pyridines
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
ATE369854T1 (de) 2001-10-19 2007-09-15 Ortho Mcneil Pharm Inc 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
JP2005515173A (ja) 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド[4,5−b]インドール誘導体
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US7202244B2 (en) 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
WO2005011597A2 (en) 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2004279427B2 (en) 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
JP4845736B2 (ja) 2003-10-14 2011-12-28 アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ プロテインキナーゼ阻害剤
US7691866B2 (en) 2003-10-16 2010-04-06 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
US20050096324A1 (en) 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
CA2561831A1 (en) 2004-04-13 2005-12-22 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2604284A1 (en) 2005-04-28 2006-11-02 Supergen, Inc. Protein kinase inhibitors
CN101213187B (zh) 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 作为rho-激酶抑制剂的异喹啉衍生物
TWI387592B (zh) * 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
JP5052518B2 (ja) 2005-10-06 2012-10-17 シェーリング コーポレイション プロテインキナーゼインヒビターとしてのピラゾロピリミジン
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
MX2009005964A (es) 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolina sustituidos con cicloalquilamina.
EP2727909A1 (en) 2007-03-16 2014-05-07 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
GB0719644D0 (en) * 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0803018D0 (en) * 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
TWI466886B (zh) * 2008-06-11 2015-01-01 Genentech Inc 二氮雜咔唑及使用方法
JP6073910B2 (ja) 2011-11-09 2017-02-01 キャンサー・リサーチ・テクノロジー・リミテッド 5−(ピリジン−2−イル−アミノ)−ピラジン−2−カルボニトリル化合物及びその治療使用
ES2624307T3 (es) 2012-05-15 2017-07-13 Cancer Research Technology Ltd 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo y usos terapéuticos del mismo

Similar Documents

Publication Publication Date Title
JP2014532751A5 (https=)
RU2014147105A (ru) 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
JP2015520753A5 (https=)
ES2923875T3 (es) Moduladores de la vía integrada del estrés
JP6147799B2 (ja) Parpインヒビターとの組合せ療法
JP2017036314A5 (https=)
JP2021502388A (ja) Ash1l阻害剤及びそれを用いた治療方法
ES2911040T3 (es) Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2)
BR112020006780A2 (pt) moduladores do estimulador de genes do interferon (sting)
TW201808914A (zh) 整合應激途徑之調節劑
BRPI0820518B1 (pt) Composto e composição farmacêutica
JP2016528246A5 (https=)
CN103180320B (zh) 1H-吡咯并[2,3-b]吡啶衍生物
JP2013512263A5 (https=)
ES2862314T3 (es) Compuestos de imidazo[1,2-a]piridina, composiciones que los comprenden, métodos para el tratamiento de enfermedades que los utilizan y métodos para prepararlos
CN1276923C (zh) 盐酸伊立替康的结晶多晶型物
JP2021505600A (ja) Nsdファミリー阻害物質及びそれによる治療の方法
BR112012033425A2 (pt) pirazoloquinolinas
TW202116770A (zh) 類鐸受體促效劑
WO2016115869A1 (zh) Flt3激酶的新型抑制剂及其用途
JP2016504325A5 (https=)
JP6978002B2 (ja) チエノ−ピリミジン誘導体およびその使用
AU2016298962A1 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
CA2922542A1 (en) Arylquinoline and analog compounds and use thereof to treat cancer
RU2014121334A (ru) Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение